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Abstract: The incidence of hypertension is rising in the general population. A parallel trend 
is present in children and adolescents. This reflects more intensive treatment and improved 
patient survival after a wide range of serious systemic illnesses that can lead to hypertension. 
In addition, primary or essential hypertension is more prevalent because of the epidemic of 
obesity and metabolic syndrome in pediatric and adult patients of both genders and in all ethnic 
groups. As a consequence of the changing demographic pattern of hypertension, more patients 
are requiring therapy for elevated blood pressure. This review summarizes key aspects of the 
treatment for hypertension in pediatric patients and the long-term management of this problem, 
including nonpharmacologic strategies and drug treatment.
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Introduction
Early reports from the 1970s and early 1980s suggested that hypertension was an 
infrequent abnormality in pediatrics, affecting, at most, 3%–5% of children. This 
figure is consistent with early studies based on a single measurement of blood pres-
sure and the statistical definition of hypertension as blood pressure exceeding the 95th 
percentile. Lower prevalence figures in the 1%–3% range were reported in studies 
that incorporated repeated measurements of blood pressure on at least three separate 
occasions. However, in recent years, there is growing documentation that hyperten-
sion is an increasingly common clinical problem in children and adolescents.1 This 
reflects the more widespread measurement of blood pressure as part of routine care 
in pediatric practice in conjunction with epidemiologic changes in dietary habits, 
exercise patterns, and obesity. In addition, more children are surviving with complex 
medical conditions that require treatment with agents that cause hypertension. As a 
consequence, there is an urgent need for general pediatricians and specialists to have 
a greater understanding of the etiology and management of hypertension in pediatric 
patients. This review summarizes current thinking about the causes of hypertension and 
outlines an approach to the short- and long-term therapy of hypertension. The treatment 
section will focus on the following clinical circumstances: (i) acute severe hyperten-
sion, (ii) chronic hypertension secondary to an underlying disease, and (iii) chronic 
asymptomatic primary hypertension.
Causes of hypertension
Hypertension in pediatric patients can either be primary or essential in nature or be 
secondary to a wide range of illnesses. The secondary causes can be categorized into Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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five broad categories: (i) renal parenchymal disease, eg, acute 
and chronic glomerulonephritides, polycystic kidney disease, 
reflux nephropathy; (ii) renal vascular hypertension; (iii) aor-
tic coarctation; (iv) endocrine disorders, eg, hyperthyroidism, 
hypercortisolism, hyperparathyroidism; (v) malignancies, 
eg, neuroblastoma, Wilms’ tumor, pheochromocytoma; and 
(vi) miscellaneous disorders, eg, Guillain–Barré syndrome, 
immobilization, illicit drug use, administration of corticos-
teroids. It is worth noting that over the last 20 years, the vast 
majority of children and adolescents referred for evaluation 
in the Pediatric Hypertension Center at Cohen Children’s 
  Medical Center (New Hyde Park, NY) have essential 
  hypertension. The most common secondary causes are reno-
vascular disease and coarctation of the aorta. This reflects 
prior identification of children with kidney disease.
The cause of hypertension emerges from a comprehensive 
history and physical examination of the patient. Laboratory 
testing usually includes a comprehensive metabolic profile, 
a lipid profile, a renal ultrasound, and an echocardiogram. 
The yield of most of these routine diagnostic tests in patients 
with mild-to-moderate hypertension is low, with less than 
10% revealing significant abnormalities.2 More specific tests, 
such as assays for plasma catecholamines and hormone levels 
and renal arteriography, should be guided by the specifics of 
the individual case. Measurement of blood pressure over a 
24-hour period using portable ambulatory monitoring devices 
is widely used and is being incorporated into the standard 
evaluation of hypertension in children.3 Normative data are 
available for this procedure, and the test provides a very 
accurate assessment of blood pressure. For example, this test 
facilitates the discrimination between healthy children with 
normal blood pressure, those with masked hypertension (nor-
mal clinic blood pressure reading and high levels at home), 
white coat hypertension (high clinic blood pressure reading 
and normal levels at home), and sustained hypertension. In 
addition, it supplies useful information that cannot be ascer-
tained by reliance solely on office measurements, including 
blood pressure load (percentage of readings above the 95th 
percentile, nocturnal dipping pattern, and mean pressure 
during specified periods of the day).
Hypertension has many causes and has important target 
organ consequences, such as left ventricular hypertrophy. 
Many subspecialists, including cardiologists, endocrinolo-
gists, and interventional radiologists, contribute to the suc-
cessful evaluation and treatment of children with high blood 
pressure. However, the vast majority (over 80% of cases) 
of secondary causes of hypertension in children arise from 
primary kidney disease.4,5 Therefore, pediatric nephrologists 
have the greatest experience in the diagnosis and management 
of children with high blood pressure. It is for this reason that it 
is recommended that pediatric patients with newly identified 
hypertension should be referred to a pediatric nephrologist 
for their initial evaluation.
Acute severe hypertension
Blood pressure readings are considered severely elevated 
if they exceed the 99th percentile or if they are more than 
20/10 mm Hg above the 95th percentile level for the child’s 
age, gender, and height.5,6 Blood pressure levels above 
the 99th percentile or more than four standard deviations 
(SDs) above the mean are considered severe, and there is 
a higher likelihood of symptoms and physical findings on 
  examination.6 However, any high blood pressure in the 
presence of neurologic symptoms is an acute emergency 
that requires urgent therapy. The differential diagnosis is as 
broad as the list of causes of asymptomatic mild   hypertension. 
However, in children, the commonest causes include acute 
glomerulonephritis, hemolytic uremic syndrome, reflux 
nephropathy, renal artery stenosis, and intoxications. Under 
these circumstances, there is a need for emergency treat-
ment to lower blood pressure sufficiently to reduce the risk 
of vasogenic edema and cerebral hemorrhage. The target of 
treatment is not to normalize the blood pressure but rather to 
lower to the mean arterial pressure by 20%.7 Once this degree 
of blood pressure lowering is accomplished, the patient can 
be started on a regular regimen of medications designed 
to completely normalize the blood pressure   readings. It 
is important to note one critical distinction between adult 
and pediatric patients with acute hypertensive crisis. In the 
former cohort, because of the presence of atherosclerosis 
and chronic vascular disease in the brain, heart, and gut, 
adequate organ perfusion may depend on maintenance of a 
relatively high perfusion pressure. Thus, acute lowering of 
blood pressure can cause vital organ ischemia and manifest 
as a myocardial infarction or cerebrovascular accident. 
  Children are less likely to have atherosclerosis and therefore 
can tolerate sudden drastic drops in blood pressure. Although 
they may complain of symptoms such as lightheadedness, 
fatigue, palpitations, and nausea, they are highly unlikely to 
experience organ   dysfunction. This makes the management 
of acute hypertensive emergencies much easier in pediatric 
patients.
In patients with severe hypertension (.4 SDs above 
the mean)6 or those in whom the elevated blood pressure is 
accompanied by symptoms, it is advisable to initiate therapy 
with parenteral medications. The first-line agent used in Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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pediatrics is labetalol. The dose is 0.25–1 mg/kg per dose 
administered by rapid infusion. The blood pressure response 
occurs within 5–10 minutes. The dose can be escalated to 
the maximal level or repeated in 30–60 minutes, depending 
on the adequacy of the response. Labetalol can also be pro-
vided as a continuous infusion, but this requires some time 
to prepare the solution and can be implemented after bolus 
injections of the drug have lowered the blood pressure to safer 
levels. A second choice is a calcium channel blocker (CCB), 
such as isradipine (0.1 dose mg/kg per dose) or nicardipine 
(0.1–0.3 µg/kg per minute). These agents, which have a peak 
hypotensive within 2.5 hours, are generally effective regard-
less of the patient’s age or the etiology of the hypertension.8 
It should be noted that short-acting nifedipine has also been 
demonstrated to be safe and effective in hospitalized patients 
with severe acute hypertensive emergencies.9 However, its use 
has been curtailed because of reports of cardiovascular com-
plications that occurred in adult patients who were given the 
drug for the control of life-threatening hypertension. A third 
option is enaliprilat, an injectable angiotensin-converting 
enzyme inhibitor (ACEI), provided in a dose of 0.005–0.1 
mg/kg per hour. Diazoxide, an agent that was widely used 
in the past, either as a single rapid infusion of 5 mg/kg or 
multiple small injections of 1 mg/kg per dose, has fallen out 
of favor because it can cause hyperglycemia and fluid reten-
tion. Moreover, in contrast to the other options, diazoxide is 
more likely to cause overshoot of the target blood pressure. 
Although hydralazine, in a dosage of 0.15–0.25 mg/kg every 
4–6 hours, is highly effective, it is associated with severe 
reflex tachycardia and nausea, and it is less well tolerated 
compared with labetalol, a CCB, or an ACEI.
If the patient is awake and fully conscious, then 
severe hypertension can be controlled with a number of 
oral   medications. These include enalapril, clonidine, and 
minoxidil. It is worth mentioning that short-acting nifedipine 
(0.3 mg/kg per dose every 4–8 hours) remains a useful 
agent in this context. If the capsule is punctured, then the 
contents of the capsule are rapidly absorbed and the blood 
pressure-lowering action is manifest within 20–30 minutes. 
There is no sublingual absorption of the drug and there is 
no pharmacodynamic rationale to administer the drug in 
this fashion. Studies have confirmed the complete absence 
of absorption of nifedipine across the buccal mucosa and 
have verified that the antihypertensive action is related to 
the amount of the drug that is swallowed and absorbed from 
the stomach.10 In addition, it is important to emphasize that 
short-acting nifedipine is safe and effective in the treatment 
of acute severe hypertension in children. As outlined, unlike 
adults with hypertension, in whom administration of short-
acting nifedipine may be associated with a higher risk of 
myocardial infarction, pediatric patients tolerate the drug 
without evidence of significant irreversible adverse events. 
It can be used during the transition period when long-acting 
agents are introduced into the treatment regimen. The drug 
options for treatment of acute hypertensive emergencies in 
children are summarized in Table 1. After acutely lowering 
the blood pressure from the severe levels that are associated 
with intracranial hemorrhage and other end-organ dysfunc-
tion, the patient will need to be started on a regimen of agents 
to completely normalize the blood pressure.
Chronic hypertension
General principles
In patients with chronic hypertension who require long-
term management, it is valuable to build on a foundation of 
healthy lifestyle choices to maximize efficacy and to reduce 
end-organ damage related to hypertension. This includes 
adoption of a healthy, balanced diet, such as the Dietary 
Approaches to Stop Hypertension (DASH) diet,11 weight 
reduction, regular exercise, smoking cessation, and relaxation 
techniques, if possible.
In adults, it has been amply documented that even in 
patients with identified hypertension, only 50% receive 
adequate treatment to completely restore normal readings.12 
It is likely that this therapeutic shortcoming also applies to 
pediatric patients. Thus, satisfactory control of blood pres-
sure requires careful follow-up and close interaction with the 
patient and his/her family to ensure that a successful regimen 
is implemented and that its benefits are sustained.
The choice of blood pressure-lowering agents will be 
guided by the nature of the underlying condition causing the 
hypertension and the presence of other comorbid conditions 
that might be adversely affected by specific drugs.
There are several important principles that need to be 
followed in prescribing drugs for the long-term control of 
hypertension in pediatric patients. First, once severe hyper-
tension is brought under control, the patient is unlikely to 
have any symptoms that are directly due to the elevated blood 
pressure. Therefore, it is imperative that agents be chosen 
that do not cause adverse effects on quality of life or under-
mine the willingness of the patient to maintain the course 
of treatment. Second, because hypertension in pediatrics is 
most common in adolescent patients, fostering adherence to 
treatment represents an integral part of the care of patients 
in this age cohort. To maximize the likelihood that pediatric 
patients will actually take their prescribed medications, it is Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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advisable to use the fewest number of agents possible and to 
try to prescribe once-daily dosing regimens. Thus, if adding 
new drugs to a regimen has failed to adequately lower blood 
pressure, it is advisable to switch to a new drug or to use a 
combination of drugs that has physiologic justification, such 
as a diuretic with an ACEI, or a β-blocker in conjunction with 
an ACEI. Finally, it is critical to take into account features 
of normal development, such as growth potential, pubertal 
status, and cognitive capacity, in designing a therapeutic plan 
to treat hypertension in pediatric patients. It is advisable to 
arrange a meeting with the patient prior to starting therapy 
to explain the rationale for treatment and the justification for 
the choice of drugs and to explain potential adverse effects, 
in order to enhance acceptance and adherence by the patient. 
The drug options for treatment of chronic hypertension in 
children are summarized in Table 2.
Management of essential hypertension
As outlined, most pediatric patients with primary hyperten-
sion deserve a trial of nonpharmacologic management to 
lower blood pressure. This applies even though there are 
preliminary data suggesting that early treatment of prehyper-
tensive adult patients with an angiotensin receptor blocker 
can delay the onset of sustained hypertension.13 A similar 
study is required in pediatric patients to determine whether 
intervention when blood pressure readings are classified as 
prehypertensive can retard or prevent the development of 
overt hypertension.
In general, children and adolescents are less responsive 
than adults to salt restriction.14 Thus, dietary therapy should 
focus on the global composition of the diet, with attention 
given to sodium, potassium, calcium, protein, fruits, and 
vegetables. Weight loss is difficult to achieve and sustain 
and usually will require concerted effort by a team of profes-
sionals, including a dietician and a nurse. There is evidence 
that loss of 10–15 pounds (4–7 kg) is sufficient to achieve 
a meaningful reduction in blood pressure. This change 
may be attributable to improved responsiveness to insulin, 
altered sympathetic nervous system activity, and reversal 
of endothelial dysfunction.15 Regular exercise of any kind, 
namely participation in physical activities that increase the 
heart rate for 30–40 minutes three to four times a week, is 
a realistic goal that leads to a demonstrable improvement 
in hypertension.16 Stress reduction using techniques such 
as yoga and biofeedback are clearly and highly effective in 
motivated patients. Nonpharmacologic options for the treat-
ment of hypertension in pediatric patients are summarized 
in Table 3.
Table 1 Drugs for use in acute hypertension
Drug Class Dose Side effects
Labetalol β-blocker 0.25–1 mg/kg per hour Dizziness, nausea, stuffy nose
Nicardipine CCB, intravenous 0.1–3 µg/kg per minute Edema, flushing
enalapril ACeI 0.005–0.01 mg/kg per hour Facial swelling, cough
Diazoxide vasodilator 1 mg/kg Hyperglycemia
Nitroprusside vasodilator 0.5–2 µg/kg per minute, titrated 
minute to minute
Cyanide intoxication
Nifedipine CCB, oral 0.3 mg/kg every 4–8 hours Edema, flushing
Abbreviations: ACeI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker.
Table 2 Drugs for use in chronic hypertension
Drug Class Dose Side effects
Chlorthalidone Diuretic 0.3–2 mg/kg per day 
Maximum: 50 mg 
Given every 24 hours
Hypokalemia, hyperglycemia, 
hyperuricemia, renal injury
enalapril ACeI 0.1–0.6 mg/kg per day 
Maximum: 40 mg 
Given every 12–24 hours
Cough, hyperkalemia, 
angioedema, decreased GFR
Losartan ARB 0.7–1.4 mg/kg per day 
Maximum: 100–150 mg 
Given every 12–24 hours
Hyperkalemia, decreased GFR
Amlodipine CCB 0.05–0.5 mg/kg per day 
Maximum: 15–20 mg 
Given every 12–24 hours
Flushing, edema, headaches
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; CCB, calcium channel blocker; GFR, glomerular filtration rate.Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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If a reasonable attempt to implement nondrug   strategies 
fails to lower blood pressure in patients with essential 
hypertension, then initiation of drug therapy is warranted. 
This approach to therapy is warranted if the child has any 
symptoms such as headache, if there are other cardiovascular 
risk factors such as obesity or hyperlipidemia, or if there is a 
family history of premature cardiovascular morbidity or early 
deaths from myocardial infarction or cerebrovascular acci-
dents. In the past, efforts were made to individualize therapy 
based on renin profiling on the ethnicity/race of the patients. 
Thus, White patients were thought to have primarily renin-
mediated hypertension, and Black patients were thought to 
have volume-mediated hypertension, and these assumptions 
were used to guide the choice of the initial therapeutic agent. 
In addition, a stepped approach was advised in which second 
and third agents were added sequentially in a formalized 
process until blood pressure was normalized.17
The results of the ALLHAT (Antihypertensive and Lipid 
Lowering Treatment to Prevent Heart Attacks Trial) and 
AASK (African American Study of Kidney Diseases and 
Hypertension) trials,18,19 which enrolled large numbers of 
White and Black adult patients, respectively, and assessed 
efficacy of antihypertensive therapy based on the impact on 
clinically significant endpoints, have significantly altered the 
way clinicians manage hypertension. ALLHAT compared 
a CCB (amlodipine), an ACEI (lisinopril), and a thiazide 
diuretic (chlorthalidone). An α-1 adrenoceptor antagonist, 
doxazosin,20 was dropped early in the study because of an 
increased risk of heart failure. The major conclusion of 
the trial was that the three drug classes were equivalent in 
antihypertensive efficacy. Thus, there is no a priori reason 
to favor one class over the other in White or Black patients 
who do not have underlying kidney disease. In view of the 
minimal cost and extended experience with thiazide diuret-
ics, these agents were seen in a new, more favorable light. 
Although criticism has been directed at this interpretation 
of ALLHAT, ie, that the CCB and ACEI doses were not 
maximized and that thoughtful combination therapy was 
proscribed, the net result has been a resurgence in the use of 
diuretics as a first-line agent in all patients with hypertension. 
In fact, although hydrochlorothiazide continues to be the 
most commonly prescribed diuretic, monitoring of national 
prescribing trends suggest that there has been a shift toward 
increased use of chlorthalidone, the drug administered in 
ALLHAT.21 It is clear that there are adverse effects from 
thiazide diuretics, including hyperglycemia, hyperlipidemia, 
and hyperuricemia. In addition, in experimental animals, 
prolonged administration of thiazide diuretics is associated 
with interstitial fibrosis and tubular atrophy that may be 
independent of drug-induced hypokalemia.22 However, with 
the recognition that the antihypertensive effect of diuretics 
requires lower doses than were prescribed in the past, these 
side effects can be minimized.
There are no comparable studies of the role of diuretics 
as first-line therapy in pediatric patients with hypertension. 
However, if anything, in view of the lower incidence of car-
diovascular and atherosclerotic heart disease in children versus 
adults, the overall safety of diuretics should be even greater in 
pediatric patients compared with in their adult counterparts.
In approximately 50% of patients with hypertension, 
the use of diuretics as a single agent will not be adequate 
to normalize blood pressure. In these cases, a second, third, 
or even fourth drug may be needed to control hypertension, 
and updated treatment guidelines by professional societies 
emphasize this point.23 It is important to emphasize that 
according to data from the National Health and Nutrition 
Examination Survey (NHANES), many patients with diag-
nosed hypertension are not provided with sufficient medica-
tion to achieve blood pressure in the normal range.12 Thus, 
physicians and nephrologists need to overcome a natural 
reluctance to prescribe additional medications, provided they 
are meticulous in trying to utilize thoughtful combinations 
and once-daily dosing and avoid agents with significant 
morbidity that will undermine patient adherence to treat-
ment. The use of these additional drugs is covered in the 
following section. The diagnosis and treatment of essential 
hypertension in children and adolescents is a costly effort, and 
recent studies have tried to identify the most cost-effective 
approach. In general, population-based strategies, such as 
reduced salt content in manufactured foods and increased 
exercise in school, yield the greatest benefit for the least 
cost. Other feasible approaches include screening and treat-
ing high-risk patients, such as those who are overweight or 
who have evidence of target organ injury, eg, left ventricular 
hypertrophy.24
Table 3 Nonpharmacologic options for treatment of pediatric 
patients with hypertension
Dietary changes
  Sodium restriction
  Potassium supplementation
  Calcium supplementation
  Magnesium supplementation
weight loss
exercise
Biofeedback
Relaxation techniques: yoga, meditationIntegrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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Management of secondary hypertension: 
nonrenal causes
There is the recognition that regardless of the underlying 
cause of hypertension, the final common pathway is increased 
peripheral vascular resistance. This was the justification for 
the use of direct vasodilators to treat elevated blood pressure 
levels. In fact, this was the mechanism of action for most of 
the drugs that were initially used to treat hypertension, eg, 
ganglionic blockers, hydralazine. However, most of these 
agents were associated with symptomatic hypotension and 
a wide range of poorly tolerated side effects. CCBs are the 
most recently developed direct vasodilators and are widely 
used precisely because of their generally favorable side 
effect profile.
The CCBs fall into three distinct molecular categories: 
dihydropyridines (eg, nifedipine), phenylalkylamines (eg, 
verapamil), and benzothiazepines (eg, diltiazem). They 
all share the property of inhibiting calcium entry into the 
vascular smooth-muscle cell via a voltage-gated channel. 
Although all three chemical types of CCBs are used in adults, 
the most widely used drugs in this class are the dihydro-
pyridines. Therefore, there is the greatest experience with 
these CCBs. These agents are available in short-acting and 
extended-release formulations. Amlodipine (0.05–0.5 mg/kg 
per day) may be the optimal CCB for use in children because 
of its enhanced binding to the calcium channel, prolonged 
elimination half-life (.30 hours), and extended duration of 
action.25,26 This facilitates once-daily dosing for control of 
hypertension in most cases. Unfortunately, the CCBs are 
available only as tablets, and a standard liquid preparation 
has not been designed that is US Food and Drug Administra-
tion (FDA) approved for use in children and demonstrated 
to be bioequivalent to tablets. This manufacturing problem 
may limit use of CCBs to older children who can swallow 
tablets.
There are several relatively common side effects of 
CCBs, including flushing, headaches, migraines, periph-
eral edema, and congestive heart failure. Less common 
but important adverse effects include gingival hyperplasia, 
chest pain, and gastrointestinal complaints such nausea and 
vomiting.
β-blockers lower blood pressure via a number of mecha-
nisms, including altered central and peripheral sympathetic 
nervous system activity, inhibition of renin release, reduction 
in cardiac output, and potentiation of the action of natriuretic 
peptides. Agents in this class have been available for over 
40 years. However, the initial drugs that were introduced 
into clinical practice were nonselective and contraindicated 
in patients with pulmonary disease, because of the risk of 
bronchoconstriction. The development of cardioselective 
β-adrenergic receptor blockers such as atenolol and meto-
prolol substantially overcame this problem. Labetalol has the 
additional property of acting as a peripheral α1-adrenergic 
blocker, which in conjunction with its β-blocker actions 
enhances its blood pressure-lowering action. It has become 
one of the most commonly prescribed β-blockers in pediatric 
patients.
β-blockers can be effective as single agents or in combi-
nation with other drugs, such as a diuretic and/or an ACEI. 
They are metabolized by the liver before entering the sys-
temic circulation, which accounts for wide variability in 
response to these drugs.
The most common side effects of β-blockers are related 
to central nervous system disturbances, including fatigue, 
depression, dizziness, and lightheadedness. Other adverse 
events associated with administration of β-blockers include 
bradycardia, postural hypotension, cold extremities, and 
nausea.
Most patients with nonrenal secondary hypertension or 
primary (essential) hypertension can achieve normal blood 
pressure using exclusively the agents described previously. 
As mentioned,23 in select cases, additional third and fourth 
agents may be required. Direct vasodilators such as hydrala-
zine and prazosin can cause reflex tachycardia, palpitations, 
and symptomatic hypotension, especially after increases 
in dosage. Hydralazine can trigger a lupus-like illness. 
  Minoxidil, the most potent vasodilator, should be avoided, if 
possible, because of the induction of hypertrichosis. This is a 
significant side effect in body image-conscious adolescents. 
Centrally acting drugs such as clonidine (0.1–0.9 mg/day 
in one to three doses) are poorly tolerated because of the 
associated drowsiness and fatigue. However, it is important 
to keep this agent in mind in difficult cases, because it is 
available as a patch that only needs to be applied weekly. 
This method of transcutaneous drug delivery can improve 
blood pressure control in adolescents who do not adhere 
to treatment recommendations, provided there is no abrupt 
interruption in application of the patch.
Management of secondary hypertension: 
renal causes
In patients with underlying renal parenchyma disease, treat-
ment of hypertension accomplishes two distinct purposes: 
(i) prevention of cardiovascular disease, including myocar-
dial infarction, congestive heart failure, and cerebrovascular 
events; and (ii) protection against progressive deterioration Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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in kidney function. Successful reduction in blood pressure 
will generally achieve both goals. The target blood pres-
sure for patients with chronic kidney disease (CKD) who 
have hypertension has been set lower compared with those 
who have normal kidney function. In adults with CKD, the 
blood pressure goal is 125–130/75–80 mm Hg.27 It is worth 
noting that recent reports, such as the AASK cohort study, 
have raised questions about the clinical benefit of more 
intensive control of blood pressure in patients with CKD. 
However, under these circumstances, there is evidence that 
use of agents that block the renin–angiotensin axis and 
the action of aldosterone may have additional benefit with 
regard to the second objective, namely renoprotection. There 
are investigators who have argued that there are no blood 
pressure-independent effects of antagonists/inhibitors of 
renin–angiotensin on renal function and claim that, provided 
there is equivalent degree of blood pressure lowering, all 
classes of antihypertensive drugs are effective in stabilizing 
renal function in patients with underlying kidney disease.29 
However, the general consensus is that agents that prevent 
the synthesis and/or action of angiotensin II and aldoster-
one have long-term renoprotective effects that exceed the 
benefits related solely to the reduction in blood pressure. 
These actions include decreased production of the profibrotic 
cytokine, transforming growth factor-β (TGF-β), reduced 
activity of proinflammatory molecules, and diminished 
production of oxygen free radicals.30,31 These molecules 
are mediators of renal injury and fibrosis in patients with 
CKD, and interference with their action by the administra-
tion of agents that inhibit the action of angiotensin II and/or 
aldosterone have been demonstrated to be beneficial in 
experimental models of CKD and a wide range of clinical 
disorders of the glomerulus and tubulointerstitium.
The first class of drugs introduced into clinical practice 
that interfered with the action of angiotensin II were the 
ACEIs, eg, captopril, enalapril, and lisinopril, in 1981. They 
were followed by the antagonists of angiotensin II type 1 
receptor blockers (ARBs), eg, losartan, in 1995. The most 
recently developed class of drugs with the general property 
of disruption of the renin–angiotensin axis are the direct 
renin inhibitors, eg, aliskiren. Finally, selective aldosterone 
antagonists, eg, eplerenone, are now available that do not 
occupy other steroid receptors or exert an antiandrogen action 
and thus are devoid of side effects of previous agents in this 
group. Based on preclinical studies, aldosterone antagonists 
reduce fibrosis by decreasing the activity of TGF-β and plas-
minogen activator inhibitor-1.32 In the RALES   (Randomized 
Aldactone Evaluation Study),33 adding spironolactone to the 
therapeutic regimen of patients with severe congestive heart 
failure lowered the incidence of death and   cardiovascular 
complications. In small, uncontrolled clinical trials, 
  administration of eplerenone has been associated with preser-
vation of renal structure and function, to a degree that exceeds 
expectation based on the degree of blood pressure reduction 
achieved with their use. These studies require confirmation 
in large-scale randomized clinical trials.
ACEIs have been part of clinical practice since the early 
1980s. They were one of the first custom-designed drugs 
whose synthesis was based on crystallographic studies of 
the structure of ACE and the selection of molecules that 
would inhibit enzymatic activity. The first drug in this class 
was captopril, which required dosing two to four times a day 
and which contained a sulfhydryl group that caused drug-
related toxicity. All currently used ACEIs are prodrugs that 
are slowly converted to the active form, enabling once-a-day 
dosing. In addition, they do not contain a sulfhydryl group 
and are less like to cause neutropenia and loss of taste.
Controlled clinical trials have verified the short-term 
efficacy of enalapril, lisinopril, ramipril, and fosinopril 
in the treatment of essential hypertension and secondary 
hypertension due to CKD in pediatric and adult patients.34,35 
They are generally successful as a single agent in 60% of 
patients (range 6%–93%). They rarely cause symptomatic 
hypertension and are associated with a very favorable impact 
on quality of life. Their efficacy is enhanced by the addition 
of a diuretic to the treatment regimen. The diuretic enhances 
renin release and potentiates the blood pressure-lowering 
action of ACEIs.
The major clinical side effects of ACEI are cough 
that occurs in up to 10% of adults and 3% of children.36 
Angioedema is another rare but potentially life-threatening 
complication that can be treated by discontinuing the ACEI. 
It rarely recurs after switching to an ARB.37 A significant 
number of patients, especially those with CKD, may experi-
ence a marked decline in kidney function if they are placed 
on an ACEI. This is an expected event based on the reduc-
tion in intrarenal angiotensin II levels and the decline in 
intraglomerular perfusion pressure. However, if the fall in 
glomerular filtration rate (GFR) is 20% or less compared with 
the pretreatment value, then the short-term adverse impact is 
outweighed by the long-term benefit of extended preservation 
of GFR.38 It is worth noting that the renoprotective effects of 
ACEIs may require larger doses than the amounts needed to 
maximally lower blood pressure. This may be related to the 
amount of drug needed to reduce the angiotensin   II-mediated 
changes in inflammatory and profibrotic mediators of CKD Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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progression, eg, TGF-β. In addition, hyperkalemia is a 
relatively frequent complication of ACEI use, especially 
in those with CKD who are given these drugs as part of 
routine clinical care.39 Thus, this group of patients requires 
close monitoring of kidney function and serum electrolyte 
concentrations when an ACEI is added to the therapeutic 
regimen.40 Finally, female patients of child-bearing age must 
be warned about the potential teratogenic effects of ACEIs 
that are applicable throughout gestation.41
ARBs represent a viable option in patients whose blood 
pressure cannot be controlled with an ACEI or who develop 
adverse events in response to the latter class of agents. They 
may have additional benefits compared with the ACEIs 
because they would inhibit the action of angiotensin II 
that is synthesized by non-ACE-dependent pathways, eg, 
  chymase.42 There is evidence from animals that the benefi-
cial effect of ARBs is related to two parallel pharmacologic 
actions: blockade of the vasoconstrictor angiotensin type 1 
(AT1) receptor and diversion of angiotensin II to the angio-
tensin type 2 (AT2) receptor. Occupancy of the latter receptor 
increases synthesis of nitric oxide, leading to vasodilatation 
and lowering of blood pressure.42
These agents have been demonstrated to be effective 
in lowering blood pressure in pediatric and adult patients. 
The overall side effect profile is similar to that of ACEIs. 
However, because they are not associated with inhibition of 
bradykinin degradation, a direct action of ACE, they have a 
lower likelihood of triggering a cough.36
Currently, there is ongoing debate about whether com-
bined use of an ACEI and an ARB yields any benefit on blood 
pressure control and protection against progressive decline 
in renal function compared with maximal use of either drug 
as a single agent.43,44 There is evidence to support both posi-
tions. The consensus on this practice point is to maximize the 
dose of each agent individually before adding a drug from 
the other class. In addition, patients prescribed both agents in 
combination require close surveillance for the development 
of hyperkalemia or a decline in GFR.39,45
One predictable response to the use of an ACEI or an 
ARB is an increase in the plasma renin activity (PRA) sec-
ondary to loss of feedback inhibition by angiotensin II. This 
compensatory rise in PRA may overcome the pharmacologic 
blockade of ACE or the AT1 receptor and account for the 
gradual loss of activity of these drugs. This has spurred the 
development of agents that directly affect the action of renin 
on angiotensinogen to form angiotensin I.45,46 Interestingly, 
part of the beneficial effect of aliskiren may be attributable 
to inhibition of the prorenin receptor, which may directly 
activate profibrotic signaling pathways within the kidney 
  independently of the AT1 receptor.47 The first drug in this 
class that has been FDA approved and introduced into 
clinical use is aliskiren. It is available in tablet form and has 
been shown to achieve a reduction in blood pressure that is 
comparable with ACEIs or ARBs. The long-term effects on 
blood pressure and renal function will be determined with 
prolonged experience with this agent. There is considerable 
controversy on whether the CCBs exert a renoprotective 
effect that is greater than the drug-induced fall in blood 
pressure, and it is for that reason that drugs that target renin–
angiotensin II are still given preference in patients with 
underlying CKD and proteinuria.48,49
In most patients with renal disease, additional drugs to 
agents that interrupt the renin–angiotensin axis are needed 
to control blood pressure. These are outlined in the previous 
section, which describes drug therapy in patients who are 
hypertensive but who do not have kidney disease.
Conclusion
Hypertension is an increasingly prevalent problem in pediat-
rics. Therefore, both general pediatricians and specialists need 
to be familiar with the therapeutic approach to treating this 
problem. Although nonpharmacologic therapy is preferred, 
it is often inadequate to normalize high blood pressure, and 
drug treatment is necessary. The goal of treatment is differ-
ent in the setting of acute life-threatening hypertension and 
sustained elevations in blood pressure due to an underlying 
disease. Regardless of the underlying cause, a regimen should 
be selected that addresses the specific clinical circumstances, 
minimizes side effects to maximize adherence, and has the 
least long-term toxicity. Further research is likely to lead to 
identification of additional therapeutic targets that will allow 
the implementation of personalized medicine for the treatment 
of hypertension. Drug development will foster the manufac-
ture of safer agents with a higher benefit:risk ratio, which, in 
turn, will alleviate some of the persistent concerns related to 
prolonged therapy of hypertension in pediatric patients.
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